Entera Bio Ltd. entered into a Securities Purchase Agreement on April 1, 2026, for a private placement of 7,827,789 units at approximately $10.0 million, intended to support their osteoporosis study and general operations. Each unit includes an ordinary share or pre-funded warrant and an ordinary share warrant, with potential additional proceeds of $14.5 million upon full exercise of the warrants.